PREDICTION OF LONG-TERM FACTOR IX DURABILITY AMONG HEMOPHILIA B PATIENTS TREATED WITH FIDANACOGENE ELAPARVOVEC GENE THERAPY

被引：0
|
作者：
Morris, A. [1 ]
Ortega, L. [2 ]
Thakkar, S. [3 ]
Wilcox, L. [4 ]
Cappelleri, J. C. [5 ]
Incerti, D. [6 ]
Ines, M. [7 ]
Deb, P. [8 ]
Chhabra, A. [9 ]
Vytlacil, E. [10 ]
Batt, K. [11 ]
Lakdawalla, D. [12 ]
机构：
[1] EntityRisk Inc, San Diego, CA USA
[2] EntityRisk Inc, Washington, DC USA
[3] Pfizer Inc, Cambridge, MA USA
[4] Pfizer Canada, Kirkland, PQ, Canada
[5] Pfizer Inc, Groton, CT USA
[6] EntityRisk Inc, San Francisco, CA USA
[7] Pfizer Inc, Lisbon, Portugal
[8] Hunter Coll, New York, NY USA
[9] Pfizer Inc, New York, NY USA
[10] Yale Univ, New Haven, CT USA
[11] EntityRisk Inc, Raleigh, NC USA
[12] USC, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO3
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [1] Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
    Cuker, A.
    Kavakli, K.
    Frenzel, L.
    Wang, J-D
    Astermark, J.
    Cerqueira, M. H.
    Iorio, A.
    Katsarou-Fasouli, O.
    Klamroth, R.
    Shapiro, A. D.
    Hermans, C.
    Ishiguro, A.
    Leavitt, A. D.
    Oldenburg, J. B.
    Ozelo, M. C.
    Teitel, J.
    Biondo, F.
    Fang, A.
    Fuiman, J.
    McKay, J.
    Sun, P.
    Rasko, J. E. J.
    Rupon, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (12): : 1108 - 1118
  • [2] Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
    Nathwani, A. C.
    Reiss, U. M.
    Tuddenham, E. G. D.
    Rosales, C.
    Chowdary, P.
    McIntosh, J.
    Della Peruta, M.
    Lheriteau, E.
    Patel, N.
    Raj, D.
    Riddell, A.
    Pie, J.
    Rangarajan, S.
    Bevan, D.
    Recht, M.
    Shen, Y. -M.
    Halka, K. G.
    Basner-Tschakarjan, E.
    Mingozzi, F.
    High, K. A.
    Allay, J.
    Kay, M. A.
    Ng, C. Y. C.
    Zhou, J.
    Cancio, M.
    Morton, C. L.
    Gray, J. T.
    Srivastava, D.
    Nienhuis, A. W.
    Davidoff, A. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21): : 1994 - 2004
  • [3] Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B
    Shah, Jinesh
    Kim, Hongseok
    Sivamurthy, Krupa
    Monahan, Paul E.
    Fries, Michael
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (02) : 227 - 237
  • [4] Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
    George, Lindsey A.
    Sullivan, Spencer K.
    Rasko, John E. J.
    Giermasz, Adam
    Samelson-Jones, Benjamin J.
    Ducore, Jonathan M.
    Teitel, Jerome M.
    McGuinn, Catherine E.
    Runowski, Alexa R.
    Wright, Fraser
    Anguela, Xavier M.
    High, Katherine A.
    Rybin, Denis
    Murphy, John E.
    Rupon, Jeremy
    BLOOD, 2019, 134
  • [5] PATTERNS OF JOINT BLEEDS IN PATIENTS WITH HEMOPHILIA B FOLLOWING FIDANACOGENE ELAPARVOVEC ADENO-ASSOCIATED VIRUS GENE THERAPY
    Rasko, J. E. J.
    Chhabra, A.
    Ducore, J. M.
    George, L. A.
    Giermasz, A.
    High, K.
    McGuinn, C. E.
    O'Brien, A.
    Rupon, J.
    Samelson-Jones, B. J.
    Smith, L. M.
    Sullivan, S. K.
    Teitel, J. M.
    Winburn, I.
    HAEMOPHILIA, 2023, 29 : 113 - 114
  • [6] Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis
    Frenzel, Laurent
    Kavakli, Kaan
    Klamroth, Robert
    Chiou, Shyh-Shin
    Shapiro, Amy D.
    Sun, Pengling
    Fuiman, Joanne
    McKay, John
    Fang, Annie F.
    Biondo, Francesca
    Plonski, Frank
    Rupon, Jeremy
    BLOOD, 2023, 142
  • [7] A MULTI-YEAR FOLLOW-UP STUDY OF FIDANACOGENE ELAPARVOVEC GENE THERAPY FOR HEMOPHILIA B
    Samelson-Jones, Benjamin J.
    George, Lindsey A.
    Rasko, John E. J.
    Giermasz, Adam
    Teitel, Jerome M.
    McGuinn, Catherine E.
    Ducore, Jonathan M.
    Pennington, Sharon
    High, Katherine A.
    Rupon, Jeremy
    Biondo, Francesca
    Fang, Annie
    Smith, Lynne M.
    Kalac, Matko
    Chhabra, Amit
    Plonski, Frank
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 112 - 112
  • [8] Health-Related Quality of Life in Adults with Hemophilia B after Receiving Gene Therapy with Fidanacogene Elaparvovec
    von Mackensen, Sylvia
    Ducore, Jonathan M.
    George, Lindsey A.
    Giermasz, Adam
    McGuinn, Catherine
    Rasko, John E. J.
    Samelson-Jones, Ben J.
    Sullivan, Spencer K.
    Teitel, Jerome M.
    Chhabra, Amit
    Fang, Annie F.
    O'Brien, Amanda
    Plonski, Frank
    Rupon, Jeremy
    Smith, Lynne
    Winburn, Ian
    BLOOD, 2023, 142
  • [9] Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy
    Samelson-Jones, Ben J.
    Sullivan, Spencer K.
    Rasko, John E. J.
    Giermasz, Adam
    George, Lindsey A.
    Ducore, Jonathan M.
    Teitel, Jerome M.
    McGuinn, Catherine E.
    O'Brien, Amanda
    Winburn, Ian
    Smith, Lynne M.
    Chhabra, Amit
    Rupon, Jeremy
    BLOOD, 2021, 138
  • [10] Gene therapy for patients with hemophilia B is superior to factor IX administration
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (23) : 1488 - 1488
12345